ื™ื•ื ืฉื ื™, 10 ืื•ื’ื•ืกื˜ 2026

CytoReason

ื˜ื›ื ื•ืœื•ื’ื™ื” 7 ื—ื•ื“ืฉื™ื ืœืคื ื™

CytoReason ืžืฉื™ืงื” ืขื•ื–ืจ AI ืœืคื™ืชื•ื— ืชืจื•ืคื•ืช

ืกื™ื˜ื•-ืจื™ื–ื•ืŸ ืžืชืœ ืื‘ื™ื‘ ืžืฉื™ืงื” ืืช LINA AI, ืขื•ื–ืจ ื•ื™ืจื˜ื•ืืœื™ ืœืคื™ืชื•ื— ืชืจื•ืคื•ืช, ื‘ื›ื ืก ื”ื‘ืจื™ืื•ืช ืฉืœ JP Morgan, ื•ืžืื™ืฆื” ืžื—ืงืจ ื‘ืืžืฆืขื•ืช ื˜ื›ื ื•ืœื•ื’ื™ื” ืžื“ื•ื™ืงืช ื”ืžื‘ื•ืกืกืช ืขืœ ื‘ื™ื•ืœื•ื’ื™ื”.

ืžืงื•ืจ: ืคืกื— ื‘ื ืกื•ืŸ
ืžื“ืข 7 ื—ื•ื“ืฉื™ื ืœืคื ื™

ื—ื‘ืจืช ื”-AI ื”ื™ืฉืจืืœื™ืช CytoReason ืžืจื—ื™ื‘ื” ืฉื•ืชืคื•ืช ืœื’ื™ืœื•ื™ ืชืจื•ืคื•ืช ืขื Sanofi ื”ืฆืจืคืชื™ืช

ื—ื‘ืจืช ื”ื‘ื™ื ื” ื”ืžืœืื›ื•ืชื™ืช ื”ื™ืฉืจืืœื™ืช CytoReason ืžืจื—ื™ื‘ื” ืืช ืฉื•ืชืคื•ืชื” ืœื’ื™ืœื•ื™ ืชืจื•ืคื•ืช ืขื ืกืื ื•ืคื™ ื‘ื”ืกื›ื ื—ื“ืฉ ืจื‘-ืฉื ืชื™ ื”ืžื•ืขืจืš ืขื“ 16 ืžื™ืœื™ื•ืŸ ื“ื•ืœืจ, ืžื” ืฉืžืกืžืŸ ืืช ื”ื”ืกื›ื ื”ืžืกื—ืจื™ ื”ื—ืžื™ืฉื™ ืฉืœื”.

ืžืงื•ืจ: ืคืกื— ื‘ื ืกื•ืŸ